Antisense-based cancer therapeutics: Are we there yet?

Expert Opinion on Emerging Drugs

Volumn 11, Issue 2, 2006, Pages 337-352

  Rayburn, Elizabeth Rose ^a,b   Wang, Hui ^a   Zhang, Ruiwen ^a  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^b University of Alabama at Birmingham   (United States)

Author keywords

Antisense oligonucleotide; Chemotherapy; Oncogene; Radiation therapy; Target validation

Indexed keywords

AEG 35156; ANTINEOPLASTIC AGENT; ANTISENSE OLIGONUCLEOTIDE; AP 12009; APRINOCARSEN; AV 4126; AV 4557; CGP 69846A; EL 625; GEMCITABINE; GENE EXPRESSION MODULATOR 231; GTI 2040; GTI 2501; INDIUM 111; INX 3001; ISIS 23722; ISIS 2503; ISIS 3521; LERAFAON; LR 3001; LY 2181308; MG 98; OBLIMERSEN; OGX 011; SPC 2996; UNCLASSIFIED DRUG; UNINDEXED DRUG; VEGLIN;

ANTINEOPLASTIC ACTIVITY; CANCER; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER RESEARCH; CANCER SURGERY; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENTIATION; DRUG RESEARCH; DRUG SAFETY; DRUG TARGETING; HUMAN; KIDNEY CARCINOMA; LIVER TOXICITY; MELANOMA; NONHUMAN; REVIEW; RISK FACTOR; STRUCTURE ACTIVITY RELATION; UNSPECIFIED SIDE EFFECT;

ANTINEOPLASTIC AGENTS; DRUG DELIVERY SYSTEMS; DRUGS, INVESTIGATIONAL; HUMANS; NEOPLASMS; OLIGONUCLEOTIDES, ANTISENSE;

EID: 33646571240     PISSN: 14728214     EISSN: None     Source Type: Journal    
DOI: 10.1517/14728214.11.2.337     Document Type: Review

References (107)

1. MELISI D, TROIANI T, DAMIANO V, TORTORA G, CIARDIELLO F: Therapeutic integration of signal transduction targeting agents and conventional anti-cancer treatments. Endocr. Relat. Cancer (2004) 11:51-68.
2. DE BONO JS, ROWINSKY EK: Therapeutics targeting signal transduction for patients with colorectal carcinoma. Br. Med. Bull. (2002) 64:227-254.
3. ZHANG R, WANG H, AGRAWAL S: Novel antisense anti-MDM2 mixed-backbone oligonucleotides: proof of principle, in vitro and in vivo activities, and mechanisms. Curr. Cancer Drug Targets (2005) 5:43-49. A case study of a second-generation MBO from antisense design to full-scale preclinical evaluation.
4. CHI KN, GLEAVE ME: Antisense approaches in prostate cancer. Expert Opin. Biol. Ther. (2004) 4:927-936. A critical review of various antisense targets in prostate cancer and the molecules being used in preclinical and clinical prostate cancer studies.
5. GOLD DG, NEGLIA JP, DUSENBERY KE: Second neoplasms after megavoltage radiation for pediatric tumors. Cancer (2003) 97:2588-2596.
6. ZAMECNIK P, STEPHENSON M: Inhibition of Rous sarcoma virus replication and cell transformation by a specific oligodeoxynucleotide. Proc. Natl. Acad. Sci. USA (1978) 75:280-284.
7. RAYBURN ER, WANG W, ZHANG R, WANG H: Antisense approaches in drug discovery and development. Prog. Drug Res. (2005) 53:227-274.
8. RAYBURN E, WANG H, HE J, ZHANG R: RNA silencing technologies in drug discovery and target validation. Letters in Drug Design and Discovery (2005) 2:1-18. A comprehensive review on various RNA silencing technologies, including antisense oligos, ribozymes and RNAi.
9. GLEAVE ME, MONIA BP: Antisense therapy for cancer. Nat. Rev. Cancer (2005) 5:468-479.
10. CROOKE S: Vitravene - another piece in the mosaic. Antisense Nucleic Acid Drug Dev. (1998) 8:vii-viii. Summary of preclinical and clinical studies of the first marketed antisense drug.
11. RAVICHANDRAN LV, DEAN NM, MARCUSSON EG: Use of antisense oligonucleotides in functional genomics and target validation. Oligonucleotides (2004) 14:49-64.
12. JONES SW, LINDSAY MA: Overview of target validation and the impact of oligonucleotides. Curr. Opin. Mol. Ther. (2004) 6:546-550.
13. SHANKAR SL, MANI S, O'GUIN KN, KANDIMALLA ER, AGRAWAL S, SHAFIT-ZAGARDO B: Survivin inhibition induces human neural tumor cell death through caspase-independent and -dependent pathways. J. Neurochem. (2001) 79:426-436.
14. ALTIERI DC: Survivin, versatile modulation of cell division and apoptosis in cancer. Oncogene (2003) 22:8581-8589.
15. PATIL SD, RHODES DG, BURGESS DJ: DNA-based therapeutics and DNA delivery systems: a comprehensive review. AAPS J. (2005) 8:E61-E77.
16. FAR RK, LEPPERT J, FRANK K, SCZAKIEL G: Technical improvements in the computational target search for antisense oligonucleotides. Oligonucleotides (2005) 15:223-233.
17. BIROCCIO A, LEONETTI C, ZUPI G: The future of antisense therapy: combination with anticancer treatments. Oncogene (2003) 22:6579-6588.
18. KIM R, EMI M, TANABE K, TOGE T: Therapeutic potential of antisense Bcl-2 as a chemosensitizer for cancer therapy. Cancer (2004) 101:2491-2502.
19. LENDVAI G, VELIKYAN I, BERGSTROM M et al.: Biodistribution of (68)Ga-labelled phosphodiester, phosphorothioate, and 2′-O-methyl phosphodiester oligonucleotides in normal rats. Eur. J. Pharm. Sci. (2005) 135:949-958. An example of the potential novel application of antisense oligos for imaging.
20. ZHENG JG, TAN TZ: Antisense imaging of colon cancer-bearing nude mice with liposome-entrapped 99m-technetium-labeled antisense oligonucleotides of c-myc mRNA. World J. Gastroenterol. (2004) 10:2563-2566.
21. WANG J, CHEN P, MRKOBRADA M, HU M, VALLIS KA, REILLY RM: Antisense imaging of epidermal growth factor-induced p21 (WAF-1/CIP-1) gene expression in MDA-MB-468 human breast cancer xenografts. Eur. J. Nucl. Med. Mol. Imaging (2003) 30:1273-1280.
22. NIMJEE SM, RUSCONI CP, SULLENGER BA: Aptamers: an emerging class of therapeutics. Ann. Rev. Med. (2005) 56:555-583. A review of protein binding oligos and their potential use for therapy.
23. WALDER RY, WALDER JA: Role of RNase H in hybrid-arrested translation by antisense oligonucleotides. Proc. Natl. Acad. Sci. USA (1988) 85:5011-5015. This historic paper details the discovery of one of the mechanisms of antisense action.
24. CROOKE ST: Molecular mechanisms of action of antisense drugs. Biochim. Biophys. Acta (1999) 1489:31-44.
25. WU H, LIMA W, ZHANG H, FAN A, SUN H, CROOKE S: Determination of the role of the human RNase H1 in the pharmacology of DNA-like antisense drugs. J. Biol. Chem. (2004) 279:17181-17189. New details have been uncovered about the RNase H-mediated actions of antisense oligos.
26. KURRECK J: Antisense technologies. Improvement through novel chemical modifications. Eur. J. Biochem. (2003) 270:1628-1644. A review of many of the modifications made to an tisense oligos during recent years.
27. AGRAWAL S: Importance of nucleotide sequence and chemical modifications of antisense oligonucleotides. Biochim. Biophys. Acta. (1999) 1489:53-68. A critical review of antisense chemistry and the structure-activity relationship of modified oligos.
28. URBAN E, NOE C: Structural modifications of antisense oligonucleotides. Il Farmaco (2003) 58:243-258.
29. DEAN N, BENNETT C: Antisense oligonucleotide-based therapeutics for cancer. Oncogene (2003) 22:9087-9096. A review of antisense oligos being used to target various molecular targets for cancer therapy.
30. ZELLWEGER T, MIYAKE H, JULY L, AKBARI M, KIYAMA S, GLEAVE M: Chemosensitization of human renal cell cancer using antisense oligonucleotides targeting the antiapoptotic gene clusterin. Neoplasia (2001) 3:360-367.
31. BARTEL F, HARRIS L, WURL P, TAUBERT H: MDM2 and its splice variant messenger RNAs: expression in tumors and down-regulation using antisense oligonucleotides. Mol. Cancer Res. (2004) 2:29-35.
32. KOLE R, WILLIAMS T, COHEN L: RNA modulation, repair and remodeling by splice switching oligonucleotides. Acta Biochim. Pol. (2004) 51:373-378. A review of one of the alternative uses for antisense oligos demonstrating the use of oligos that do not activate RNase H.
33. PRAKASH TP, JOHNSTON JF, GRAHAM MJ, CONDON TP, MANOHARAN M: 2′-O-[2-[(N,N-dimethylamino)oxy]ethyl]-modified oligonucleotides inhibit expression of mRNA in vitro and in vivo. Nucleic Acids Res. (2004) 32:828-833.
34. AGRAWAL S, ZHAO Q: Mixed backbone oligonucleotides: improvement in oligonucleotide-induced toxicity in vivo. Antisense Nucleic Acid Drug Dev. (1998) 8:135-139. One of the representative early publications about second-generation mixed-backbone antisense oligos.
35. ZHANG Z, LI M, WANG H, AGRAWAL S, ZHANG R: Antisense therapy targeting MDM2 oncogene in prostate cancer: effects on proliferation, apoptosis, multiple gene expression, and chemotherapy. Proc. Natl. Acad. Sci. USA (2003) 100:11636-11641. Detailed in vitro and in vivo investigation of a second-generation mixed-backbone antisense oligo targeting the MDM2 oncogene.
36. PRASAD G, WANG H, AGRAWAL S, ZHANG R: Antisense ami-MDM2 oligonucleotides as a novel approach to the treatment of glioblastoma multiforme. Anti-Cancer Res. (2002) 22:107-116.
37. RAY A, NORDEN B: Peptide nucleic acid (PNA): its medical and biotechnical applications and promise for the future. FASEB J. (2000) 14:1041-1060.
38. TAMM I: Antisense therapy in clinical oncology: preclinical and clinical experiences. Methods Mol. Med. (2005) 106:113-134.
39. RIEDEL F, GOTTE K, LI M, HORMANN K, GRANDIS JR: Abrogation of VEGF expression in human head and neck squamous cell carcinoma decreases angiogenic activity in vitro and in vivo. Int. J. Oncol. (2003) 23:577-583.
40. NIWA H, WENTZEL AL, LI M, GOODING WE, LUI VW, GRANDIS JR: Antitumor effects of epidermal growth factor receptor antisense oligonucleotides in combination with docetaxel in squamous cell carcinoma of the head and neck. Clin. Cancer Res. (2003) 9:5028-5035.
41. LAHN M, KLOEKER S, BERRY BS: TGF-β inhibitors for the treatment of cancer. Expert Opin. Investig. Drugs. (2005) 14:629-643.
42. PESSION A, TONELLI R, FRONZA R et al.: Targeted inhibition of NMYC by peptide nucleic acid in N-myc amplified human neuroblastoma cells: cell-cycle inhibition with induction of neuronal cell differentiation and apoptosis. Int. J. Oncol. (2004) 24:265-272.
43. CUMMINGS J, WARD TH, LACASSE E et al.: Validation of pharmacodynamic assays to evaluate the clinical efficacy of an antisense compound (AEG 35156) targeted to the X-linked inhibitor of apoptosis protein XIAP. Br. J. Cancer (2005) 92:532-538.
44. HOLMLUND JT: Applying antisense technology: affinitak and other antisense oligonucleotides in clinical development. Ann. NY Acad. Sci. (2003) 1002:244-251.
45. HAYWARD RL, MACPHERSON JS, CUMMINGS J, MONIA BP, SMYTH JF, JODRELL DI: Enhanced oxaliplatin-induced apoptosis following antisense Bcl-xl down-regulation is p53 and Bax dependent: genetic evidence for specificity of the antisense effect. Mol. Cancer Ther. (2004) 3:169-178.
46. ZHANG Z, WANG H, PRASAD G et al.: Radiosensitization by antisense anti-MDM2 mixed-backbone oligonucleotide in in vitro and in vivo human cancer models. Clin. Cancer Res. (2004) 10:1263-1273.
47. RAIT AS, PIROLLO KF, ULICK D, CULLEN K, CHANG EH: HER-2-targeted antisense oligonucleotide results in sensitization of head and neck cancer cells to chemotherapeutic agents. Ann. NY Acad. Sci. (2003) 1002:78-89.
48. MANI S, GOEL S, NESTEROVA M et al.: Clinical studies in patients with solid tumors using a second-generation antisense oligonucleotide (GEM-231) targeted against protein kinase A type I. Ann. NY Acad. Sci. (2003) 1002:252-262.
49. KO YJ, DEVI GR, LONDON CA et al.: Androgen receptor down-regulation in prostate cancer with phosphorodiamidate morpholino antisense oligomers. J. Urol. (2004) 172:1140-1144.
50. BIANCO R, CIARDIELLO F, TORTORA G: Chemosensitization by antisense oligonucleotides targeting MDM2. Curr. Cancer Drug Targets. (2005) 5:51-56.
51. BALTOGIANNIS D, CHARALABOPOULOS K, GIANNAKOPOULOS X, KARAKOSTA A, SOFIKITIS N: Combined use of antisense oligonucleotides and chemotherapeutics in the treatment of refractory prostate cancer. Exp. Oncol. (2005) 27:91-93.
52. ZAFFARONI N, PENNATI M, DAIDONE MG: Survivin as a target for new anticancer interventions. J. Cell. Mol. Med. (2005) 9:360-372.
53. AGRAWAL S, KANDIMALLA E, YU D et al.: Potentiation of antitumor activity of irinotecan by chemically modified oligonucleotides. Int. J. Oncol. (2001) 18:1061-1069.
54. WANG H, NAN L, YU D, AGRAWAL S, ZHANG R: Antisense anti-MDM2 oligonucleotides as a novel therapeutic approach to human breast cancer: in vitro and in vivo activities and mechanisms. Clin. Cancer Res. (2001) 7:3613-3624.
55. WANG H, WANG S, NAN L, YU D, AGRAWAL S, ZHANG R: Antisense anti-MDM2 mixed backbone oligonucleotides enhance therapeutic efficacy of topoisomerase I inhibitor irinotecan in nude mice bearing human cancer xenografts: in vivo activity and mechanisms. Intl. J. Oncol. (2002) 20:745-752.
56. WANG H, OLIVER P, ZHANG Z, AGRAWAL S, ZHANG R: Chemosensitization and radiosensitization of human cancer by antisense anti-MDM2 oligonucleotides: in vitro and in vivo activities and mechanisms. Ann. NY Acad. Sci. (2003) 1002:217-235.
57. KLASA RJ: Targeting the proapoptotic factor Bcl-2 in non-Hodgkin's lymphoma. Oncology (2004) 18:25-31.
58. TOLCHER AW, CHI K, KUHN J et al.: A Phase II, pharmacokinetic, and biological correlative study of oblimersen sodium and docetaxel in patients with hormone-refractory prostate cancer. Clin. Cancer Res. (2005) 11:3854-3861.
59. DAVIS AJ, GELMON KA, SIU LL et al.: Phase I and pharmacologic study of the human DNA methyltransferase antisense oligodeoxynucleotide MG98 given as a 21-day continuous infusion every 4 weeks. Invest. New Drugs. (2003) 21:85-97.
60. OZA AM, ELIT L, SWENERTON K et al.: Phase II study of CGP 69846A (ISIS 5132) in recurrent epithelial ovarian cancer: an NCIC clinical trials group study (NCIC IND.116). Gynecol. Oncol. (2003) 89:129-133.
61. TOLCHER AW, REYNO L, VENNER PM et al.: A randomized Phase II and pharmacokinetic study of the antisense oligonucleotides ISIS 3521 and ISIS 5132 in patients with hormone-refractory prostate cancer. Clin. Cancer Res. (2002) 8:2530-2535.
62. CRIPPS MC, FIGUEREDO AT, OZA AM et al.: Phase II randomized study of ISIS-3521 and ISIS-5132 in patients with locally advanced or metastatic colorectal cancer: a National Cancer Institute of Canada clinical trials group study. Clin. Cancer Res. (2002) 8:2188-2192.
63. RUDIN CM, MARSHALL JL, HUANG CH et al.: Delivery of a liposomal c-raf-1 antisense oligonucleotide by weekly bolus dosing in patients with advanced solid tumors: a Phase I study. Clin. Cancer Res. (2004) 10:7244-7251.
64. CUNNINGHAM CC, HOLMLUND JT, GEARY RS et al.: A Phase I trial of H-ras antisense oligonucleotide ISIS-2503 administered as a continuous intravenous infusion in patients with advanced carcinoma. Cancer (2001) 92:1265-1271.
65. ADJEI AA, DY GK, ERLICHMAN C et al.: A Phase I trial of ISIS 2503, an antisense inhibitor of H-ras, in combination with gemcitabine in patients with advanced cancer. Clin. Cancer Res. (2003) 9:115-123.
66. ALBERTS SR, SCHROEDER M, ERLICHMAN C et al.: Gemcitabine and ISIS-2503 for patients with locally advanced or metastatic pancreatic adenocarcinoma: a North Central Cancer Treatment Group Phase II trial. J. Clin. Oncol. (2004) 22:4944-4950.
67. ORR RM: Technology evaluation: leukemia therapy, University of Pennsylvania. Curr. Opin. Mol. Ther. (1999) 1:399-403.
68. ARORA V, CATE ML, GHOSH C, IVERSEN PL: Phosphorodiamidate morpholino antisense oligomers inhibit expression of human cytochrome P450 3A4 and alter selected drug metabolism. Drug Metab. Dispos. (2002) 30:757-762.
69. SARMIENTO UM, PEREZ JR, BECKER JM, NARAYANAN R: In vivo toxicological effects of rel A antisense phosphorothioates in CD-1 mice. Antisense Res. Dev. (1994) 4:99-107.
70. KRIEG AM, YI AK, MATSON S et al.: CpG motifs in bacterial DNA trigger direct B-cell activation. Nature (1995) 374:546-549.
71. LEVIN AA: A review of the issues in the pharmacokinetics and toxicology of phosphorothioate antisense oligonucleotides. Biochim. Biophys. Acta. (1999) 1489:69-84.
72. CHI KN, EISENHAUER E, FAZLI L et al.: A Phase I pharmacokinetic and pharmacodynamic study of OGX-011, a 2′-methoxyethyl antisense oligonucleotide to clusterin, in patients with localized prostate cancer. J. Natl. Cancer Inst. (2005) 97:1287-1296.
73. LAHN M, PATERSON BM, SUNDELL K, MA D: The role of protein kinase C-α (PKC-α) in malignancies of the gastrointestinal tract. Eur. J. Cancer. (2004) 40:10-20.
74. MARCUCCI G, STOCK W, DAI G et al.: Phase I study of oblimersen sodium, an antisense to Bcl-2, in untreated older patients with acute myeloid leukemia: pharmacokinetics, pharmacodynamics, and clinical activity. J. Clin. Oncol. (2005) 23:3404-3411.
75. SHANKAR P, MANJUNATH N, LIEBERMAN J: The prospect of silencing disease using RNA interference. JAMA (2005) 293:1367-1373. A review of the advantages of and problems facing therapeutic use of RNAi.
76. LYSIK M, WU-PONG S: Innovations in oligonucleotide drug delivery. J. Pharm. Sci. (2003) 92:1559-1573.
77. VAN OEKELEN D, LUYTEN WH, LEYSEN JE: Ten years of antisense inhibition of brain G-protein-coupled receptor function. Brain Res. Brain Res. Rev. (2003) 42:123-142.
78. GARCIA-CHAUMONT C, SEKSEK O, GRZYBOWSKA J, BOROWSKI E, BOLARD J: Delivery systems for antisense oligonucleotides. Pharmacol. Ther. (2000) 87:255-277.
79. ESCRIOU V, CARRIERE M, SCHERMAN D, WILS P: NLS bioconjugates for targeting therapeutic genes to the nucleus. Adv. Drug Deliv. Rev. (2003) 55:295-306.
80. ASTRIAB-FISHER A, FISHER M, JULIANO R, HERDEWIJN P: Increased uptake of antisense oligonucleotides by delivery as double stranded complexes. Biochem. Pharmacol. (2004) 68:403-407.
81. LI Z, ZHU S, GAN K et al.: Poly-L-lysine-modified silica nanoparticles: a potential oral gene delivery system. J. Nanosci. Nanotechnol. (2005) 5:1199-1203.
82. LOCHMANN D, WEYERMANN J, GEORGENS C, PRASSL R, ZIMMER A: Albumin-protamine-oligonucleotide nanoparticles as a new antisense delivery system. Part 1: physicochemical characterization. Eur. J. Pharm. Biopharm. (2005) 59:419-429.
83. WEYERMANN J, LOCHMANN D, GEORGENS C, ZIMMER A: Albumin-protamine- oligonucleotide-nanoparticles as a new antisense delivery system. Part 2: cellular uptake and effect. Eur. J. Pharm. Biopharm. (2005) 59:431-438.
84. PASTORINO F, BRIGNOLE C, MARIMPIETRI D et al.: Targeted delivery of oncogene-selective antisense oligonucleotides in neuroectodermal tumors: therapeutic implications. Ann. NY Acad. Sci. (2004) 1028:90-103.
85. BRIGNOLE C, MARIMPIETRI D, PAGNAN G et al.: Neuroblastoma targeting by c-myb-selective antisense oligonucleotides entrapped in anti-GD(2) immunoliposome: immune cell-mediated anti-tumor activities. Cancer Lett. (2005) 228:181-186.
86. SPRINGATE CM, JACKSON JK, GLEAVE ME, BURT HM: Efficacy of an intratumoral controlled release formulation of clusterin antisense oligonucleotide complexed with chitosan containing paclitaxel or docetaxel in prostate cancer xenograft models. Cancer Chemother. Pharmacol. (2005) 56:239-247.
87. KIPSHIDZE NN, PORTER TR, DANGAS G et al.: Systemic targeted delivery of antisense with perflourobutane gas microbubble carrier reduced neointimal formation in the porcine coronary restenosis model. Cardiovasc. Radiat. Med. (2003) 4:152-159.
88. ZHANG XX, CUI CC, XU XG, HU XS, FANG WH, KUANG BJ: In vivo distribution of c-myc antisense oligodeoxynucleotides local delivered by gelatin-coated platinum-indium stents in rabbits and its effect on apoptosis. Chin. Med. J. (Engl.) (2004) 117:258-263.
89. ROTH C, SUNDARAM S: Engineering synthetic vectors for improved DNA delivery: insights from intracellular pathways. Ann. Rev. Biomed. Eng. (2004) 6:397-426.
90. ZHANG S, XU Y, WANG B, QIAO W, LIU D, LI Z: Cationic compounds used in lipoplexes and polyplexes for gene delivery. J. Control Release (2004) 100:165-180.
91. ZHAO Q, TEMSAMANI J, IADAROLA PL, AGRAWAL S: Modulation of oligonucleotide-induced immune stimulation by cyclodextrin analogs. Biochem. Pharmacol. (1996) 52:1537-1544.
92. WEBB M, TORTORA N, CREMESE M et al.: Toxicity and toxicokinetics of a phosphorothioate oligonucleotide against the c-myc oncogene in cynomolgus monkeys. Antisense Nucleic Acid Drug Dev. (2001) 11:155-163.
93. AGRAWAL S, ZHAO Q, JIANG Z, OLIVER C, GILES H, HEATH J, SEROTA D: Toxicologic effects of an oligodeoxynucleotide phosphorothioate and its analogs following intravenous administration in rats. Antisense Nucleic Acid Drug Dev. (1997) 7:575-584.
94. HENRY S, ZUCKERMAN J, ROJKO J et al.: Toxicological properties of several novel oligonucleotide analogs in mice. Anti-Cancer Drug Des. (1997) 12:1-14.
95. JASON TL, KOROPATNICK J, BERG RW: Toxicology of antisense therapeutics. Toxicol. Appl. Pharmacol. (2004) 201:66-83.
96. KRIEG AM: CpG motifs in bacterial DNA and their immune effects. Ann. Rev. Immunol. (2002) 20:709-760. A review of the effects of CpG-containing oligos on the immune system.
97. AGRAWAL S, IADAROLA P, TEMSAMANI J, ZHAO Q, SHAW D: Effect of G-rich sequences on the synthesis, purification, binding, cell uptake, and hemolytic activity of oligonucleotides. Bioorg. Med. Chem. Lett. (1996) 6:2219-2224.
98. LAI JC, BENIMETSKAYA L, SANTELLA RM, WANG Q, MILLER PS, STEIN CA: G-3139 (oblimersen) may inhibit prostate cancer cell growth in a partially bis-CpG-dependent non-antisense manner. Mol. Cancer Ther. (2003) 2:1031-1043.
99. RAOOF AA, CHIU P, RAMTOOLA Z et al.: Oral bioavailability and multiple dose tolerability of an antisense oligonucleotide tablet formulated with sodium caprate. J. Pharm. Sci. (2004) 93:1431-1439.
100. WANG H, RAYBURN E, ZHANG R: Synthetic oligodeoxynucleotides containing deoxycitidyl-deoxyguanosine dinucleotides (CpG ODNs) and modified analogues as novel anticancer therapeutics. Curr. Pharm. Des. (2005) 11:2889-2907. A comprehensive review of the various applications of CpG oligos and their effects on the immune system.
101. WOOLDRIDGE JE, WEINER GJ: CpG DNA and cancer immunotherapy: orchestrating the antitumor immune response. Curr. Opin. Oncol. (2003) 15:440-445.
102. LONG MB, JONES JP 3rd, SULLENGER BA, BYUN J: Ribozyme-mediated revision of RNA and DNA. J. Clin. Invest. (2003) 112:312-318.
103. ROGERS CS, VANOYE CG, SULLENGER BA, GEORGE AL JR: Functional repair of a mutant chloride channel using a trans-splicing ribozyme. J. Clin. Invest. (2002) 110:1783-1789.
104. CITTI L, RAINALDI G: Synthetic hammerhead ribozymes as therapeutic tools to control disease genes. Curr. Gene Ther. (2005) 5:11-24. A critical review of the various potential therapeutic uses of ribozymes.
105. SONTHEIMER EJ: Assembly and function of RNA silencing complexes. Nat. Rev. Mol. Cell Biol. (2005) 6:127-138.
106. SILVA J, CHANG K, HANNON GJ, RIVAS FV: RNA-interference-based functional genomics in mammalian cells: reverse genetics coming of age. Oncogene (2004) 23:8401-8409.
107. BERTRAND JR, POTTIER M, VEKRIS A, OPOLON P, MAKSIMENKO A, MALVY C: Comparison of antisense oligonucleotides and siRNAs in cell culture and in vivo. Biochem. Biophys. Res. Commun. (2002) 296:1000-1004.